JWH 073 N-(4-hydroxybutyl) metab

Confirm delete?

JWH 073 N-(4-hydroxybutyl) metabolite-d₅

Zoom

Cat No: 10934

Biochemicals - Isotopically Labeled Standards

JWH 073 N-(4-hydroxybutyl) metabolite-d5 contains five deuterium atoms at the 2', 4' ,5', 6', and 7' positions. It is intended for use as an internal standard for the quantification of JWH 073 N-(4-hydroxybutyl) metabolite by GC- or LC-MS. JWH 073 is ...

This article is not for sale online.
Contact us for more information about this article.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

                                            Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
                    

                        Special Advice: Please check regulation status before ordering; additionel fees can apply. 
                    

Synonyms:

(1-(4-hydroxybutyl)-1H-indol-3-yl-2',4',5',6',7'-d5)(naphthalen-1-yl)-methanone

Correlated keywords:

M2 M-2 M 2 JWH-073-M2 JWH-018-M-2 JWH-073-M M3 M-3 M 3 JWH-073-M3 JWH-073-M-3 JWH-073-M M4 M-4 M 4 JWH-018-M4 JWH-073-M-4 JWH-073-M M5 M-5 M 5 JWH-073-M5 JWH-073-M-5 JWH-073-M M6 M-6 M 6 JWH-073-M6 JWH-073-M-6 JWH-073-M deuterated deuterium metabolites cannabinoids receptors WIN 55,212-2 WIN 55212-2 CB1 CB2 cannabimimetics urine urinary metabolites glucuroconjugate forensics JWH 073 Metabolite 5 JWH-073 smoking JWH073 CBs mixtures spices analytical references standards

Product Overview:
JWH 073 N-(4-hydroxybutyl) metabolite-d5 contains five deuterium atoms at the 2', 4' ,5', 6', and 7' positions. It is intended for use as an internal standard for the quantification of JWH 073 N-(4-hydroxybutyl) metabolite by GC- or LC-MS. JWH 073 is a mildly selective agonist of the central cannabinoid (CB1) receptor derived from the aminoalkylindole WIN 55,212-2. The Ki values for binding CB1 and the peripheral cannabinoid (CB2) receptor are 8.9 and 38 nM, respectively for a CB1:CB2 ratio of 0.23.{16797} JWH 073 is one of several synthetic CBs which have been included in smoking mixtures. JWH 073 N-(4-hydroxybutyl) metabolite is expected to be a major urinary metabolite of JWH 073, characterized by monohydroxylation of the N-alkyl chain, based on the metabolism of the closely-related JWH 015 and JWH 018.{18292,18291} In urine samples, this metabolite of JWH 018 is almost completely glucuronidated.{18291}

Size	1 mg
Shipping	dry ice
CAS Number	2484976-96-5
Molecular Formula	C₂₃H₁₆D₅NO₂
SMILES	O=C(C1=C([2H])N(CCCCO)C2=C([2H])C([2H])=C([2H])C([2H])=C12)C3=CC=CC4=C3C=CC=C4
Molecular Weight	348,5
Formulation	A solution in methanol
Purity	≥99% deuterated forms (d1-d5)
Custom Code	2933.49
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.